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1. Introduction 
Major depressive disorder (MDD) is a debilitating and often recurrent psychiatric illness 
that impacts the lives of millions. Approximately 20 percent of individuals will experience at 
least one depressive episode during their lives, and the high rates of chronic morbidity 
(depressive episodes typically last for several months) and mortality (owing to suicide) 
attributed to this disorder constitute one of the largest global economic disease burdens 
(Kessler et al., 2005). Despite the considerable burden of depression, our understanding of 
its pathophysiology and the therapeutic mechanisms of action of antidepressant drugs 
remains incomplete. In fact, much of what we currently understand about the 
neuropathology of depression is derived from the observed effects of known 
antidepressants on the brain. This situation is confounded by the fact that currently 
available antidepressant drugs are of limited clinical efficacy – the antidepressant response 
typically takes several weeks to develop, and a substantial proportion of patients do not 
experience a significant improvement in depressive symptoms, or full clinical remission. 
Furthermore, because antidepressant efficacy varies significantly as a function of symptom 
severity, the benefit of antidepressant therapy may be limited or nonexistent in patients with 
mild to moderate depressive symptoms, which represent the majority of clinical cases 
(Fournier et al., 2010). When the inadequate efficacy profiles of antidepressant drugs are 
weighed against our limited understanding of depression, the therapeutic action of 
antidepressants, and the potential negative side effects of these drugs arising from 
nonspecific actions, a difficult question arises: do the benefits of antidepressant 
pharmacotherapy outweigh the risks?  
In this chapter, we explore the development of the current theories of depression etiology, 
the hindrances of current antidepressant therapeutics, and how the poor understanding of 
the mechanism of antidepressant action contributes to a haphazard interpretation of the 
benefits and consequences arising from their non-specific interactions. Through the use of a 
simple single-synapse experimental approach, we have gained insights into the impact of 
non-specific antidepressant actions on neuronal function, and our findings will be discussed 
in this context. Finally, we will explore prospective developments in the field of depression 
pharmacotherapy that may hold the potential to revolutionize the way we understand and 
treat depression. 
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1.1 Identifying & understanding depression 
Depression is a prevalent psychiatric condition in which the depressive affect (the 
immediate emotional state and a normal emotional response) becomes sustained and 
predominant, thus constituting a disorder of mood (a sustained emotional state). It is 
characterized by persistent emotional symptoms including a dysphoric mood and 
anhedonia (loss of interest or pleasure), low self-esteem, feelings of guilt, anguish, apathy 
and pessimism, and thoughts of suicide or death. Additional biological symptoms include 
difficulty concentrating and remembering, disturbances of sleep and appetite, loss of energy 
and libido, and psychomotor agitation (restlessness) or psychomotor retardation (slowing of 
thoughts and actions). The clinical diagnosis of depression is subjective, being based on the 
concurrent presence of a depressed mood, and a number of the above-mentioned biological 
symptoms, for a period of at least two weeks.  
Because the understanding of the pathophysiology of depression is limited, reliable 
indicators of risk have not yet been identified. The multitude of symptom profiles that 
constitute a diagnosis of depression points to the heterogeneous nature of the disorder, and 
its probable multifactorial and polygenic etiology. Indeed, the heterogeneity of depression is 
evident in the markedly different occurrence of depressive symptoms, genetic 
predispositions, and environmental risk factors such as stressful life events, among patients 
that present with MDD. Depression has a strong genetic predisposition, with an estimated 
heritability of 40 percent (Krishnan & Nestler, 2008; Sullivan et al., 2000); and while genetic 
association studies have identified some MDD susceptibility genes, several of which play a 
role in monoaminergic neurotransmission and neuroplasticity, findings have often been 
inconsistent, and the role of genetic polymorphisms in the manifestation of MDD remains 
uncertain (López-León et al., 2008; Pezawas et al., 2008). The roles of monoamine 
neurotransmitters and neuroplasticity in depression will be further explored below. 
The linear relationship between genetic mutations and inherited disorders, which has 
proven useful in understanding numerous other conditions (such as familial Alzheimer’s 
disease or Huntington’s disease), is not so evident in psychiatric disorders, where it is likely 
that complex interactions between genes and the environment influence neuronal networks, 
and ultimately behaviour. A polymorphism in the serotonin transporter (5-HTT) gene, 
which modulates serotonergic neurotransmission, was found to influence the occurrence of 
depression in response to stressful life events, providing the first direct evidence for the 
interplay of genes and the environment in the etiology of depression (Caspi et al., 2003). The 
strong contribution of both genetics and the environment to MDD provides a feasible 
starting point from which we can begin to understand and interpret the heterogeneity of 
depression, and ultimately, perhaps, even predict or prevent its onset. 
1.2 Depression etiology: Insights from antidepressant drugs 
Advances in understanding the etiology and developing effective therapeutics for MDD – 
and numerous psychiatric and neurodegenerative illnesses, for that matter – have lagged 
considerably behind other areas of medical research, the primary obstacle being the inherent 
complexity of the human brain. Research in the field of mood disorders has been hindered 
by both the difficulty of studying the brain directly (though modern imaging techniques 
have enabled considerable progress in this area), and the lack of truly representative animal 
models, where, while biological correlates of the disorder can be induced in animal models, 
the emotional and psychological characteristics that define the human condition are far from 
accurately paralleled.  
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The mechanistic understanding of both MDD and the therapeutic mode of action of 
antidepressants has been slow to follow the development and clinical application of 
antidepressant medication, particularly because the desired outcome of drug treatment is 
readily apparent as an elevation of mood and alleviation of depressive symptoms, whereas 
reversal of the causative brain abnormalities underlying MDD, such as neurochemical 
imbalance and/or structural alterations, are not so evident. A case in point, the primary 
theories of the etiology of depression have developed not from identifying the factors that 
underlie the neuropathology of MDD, but rather from observing the effects of 
antidepressant drugs on the brain and interpreting the roles of these target neuronal 
systems in behaviour. 
1.2.1 The monoamine hypothesis 
The monoaminergic theory of depression posits that the cause of depression is a functional 
deficit in monoaminergic neurotransmission, due to the decreased availability of 
monoamine neurotransmitters, of which serotonin (5-Hydroxytryptamine; 5-HT) has 
received considerable attention in depression. Developed from early observations that drugs 
fortuitously discovered to exert antidepressant effects all appeared to target monoaminergic 
systems, the monoamine hypothesis was the first biochemical theory of depression, and 
remains one of the main etiological hypotheses of the disorder (Schildkraut, 1965; Lapin et 
al., 1969). Serotonin in particular plays a dynamic role in the regulation of mood, cognition, 
attention, learning, appetite, sleep, motor function and the response to stress (Martinowich 
& Lu, 2008; Oberlander et al., 2009). In accordance with the monoamine hypothesis, there is 
an obvious parallel between the symptomatic disruption of mood and behaviour in 
depression, and the normal physiological role of serotonin. 
The monoamine theory of MDD provides the most logical basis for understanding the 
therapeutic mode of action of antidepressant drugs, as nearly all available antidepressants 
act by potentiating the synaptic availability of monoamine neurotransmitters (López-Muñoz 
& Alamo, 2009), which will be further explored below. Whereas antidepressants produce a 
rapid biochemical effect and an almost immediate enhancement of chemical 
neurotransmission, there is a substantial delay in the onset of antidepressant action. 
Achieving clinical improvement in depressive symptoms requires several weeks of 
continuous antidepressant administration, highlighting two obvious limitations of both 
current antidepressant medications and the monoamine theory of depression: firstly, the 
prolonged period of therapeutic inefficacy provides a large window during which 
depressive symptoms remain untreated, and suicide risk is high (Licinio & Wong, 2005); and 
secondly, such a delay in the onset of antidepressant action indicates that the cause of 
depression is not simply a deficit of monoamine neurotransmitters. 
1.2.2 The Neuroplasticity hypothesis 
A recent neuroplasticity theory of MDD gaining acceptance and substantial evidentiary 
support posits that depression results from disruptions of neuronal plasticity (structural and 
functional alterations of the brain in response to environmental changes) at various regions 
of the brain (Pittenger & Duman, 2008). In depressed patients, post-mortem and 
neuroimaging studies have identified neuronal atrophy and aberrant activity patterns in 
several brain structures, most notably in the prefrontal cortex, hippocampus and amygdala 
(Zou et al., 2010; Drevets, 2001; Krishnan & Nestler, 2008). Remarkably, chronic stress, an 
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environmental risk factor known to contribute to the development depression, also affects 
neuroplasticity in similar brain regions. These affected structures are responsible for various 
aspects of cognition, including executive functions (prefrontal cortex), emotional response 
(amygdala) and memory formation (hippocampus). Again, the normal functions of the brain 
regions disrupted by chronic stress and MDD parallel the symptomatology of depression, 
pointing to an underlying role for dysfunctional neuronal plasticity in the etiology of MDD.  
A powerful facet of the neuroplastic hypothesis is the ability to explain the delayed onset of 
antidepressant drug effects. Through a slower-acting secondary neuroplastic mechanism, 
long-term adaptive changes in the brain in response to antidepressants are thought to be 
responsible for the clinical improvement of depressive symptoms. Indeed, following chronic 
antidepressant treatment, the occurrence of structural and functional changes and enhanced 
neurogenesis that normalize neuronal networks and activity patterns correlates with the 
onset of the therapeutic response, and are likely to play a causal role in antidepressant 
action (Ressler & Mayberg, 2007; Santarelli et al., 2003; Maya Vetencourt et al., 2008). 
Though we lack a clear understanding of the mechanistic action of antidepressants, there is 
an apparent relationship between the mechanisms of neuroplasticity and MDD 
neuropathology, which has been illuminated by the molecular and cellular changes in the 
brain brought about by antidepressant action. The implication of neuroplasticity in MDD 
lends to the exciting possibility that the cellular and molecular mechanisms of synaptic 
plasticity may be effective and more direct targets for antidepressant therapeutics, 
providing prospective directions for investigation in a field of pharmacology that has been 
stagnant for decades. 
1.2.3 Linking monoamines, neuroplasticity & antidepressants 
 The slow onset of therapeutic effects of antidepressant drugs that rapidly increase synaptic 
levels of monoamine neurotransmitters necessitated the development of an alternative 
neuromodulatory hypothesis for the mechanism of therapeutic action of antidepressant 
medication. However, the monoaminergic and neuroplasticity theories of depression are not 
mutually exclusive, as monoamines are modulatory neurotransmitters that influence 
neurogenesis and neuron survival, neuronal activity, synaptogenesis and synaptic plasticity 
by initiating molecular signalling cascades. In particular, changes in the expression levels or 
function of neurotrophic factors, such as brain-derived neurotrophic factor (BDNF), a 
growth factor that is a key regulator of synaptic plasticity and participates in a 
developmental feed-back loop with serotonin, has been suggested to underlie both 
depression neuropathology and the therapeutic antidepressant response (Martinowich & 
Lu, 2008). Studies demonstrating that levels of BDNF and BDNF-mediated signalling are 
reduced in depressed patients and increased patients receiving antidepressant medication 
provide a link between the expression of BDNF and the therapeutic action of 
antidepressants (Shimizu et al., 2003; Chen, 2001). This notion is further supported by 
evidence that BDNF signalling is necessary for mediating the antidepressant response in 
animal models (Saarelainen et al., 2003). How exactly this BDNF-mediated neuroplasticity 
contributes to the emotional and behavioural response in antidepressant treatment remains 
unidentified. 
The intracellular signal transduction cascades connecting serotonin neurotransmission and 
BDNF expression provide a workable explanation for the ability of antidepressants that 
potentiate monoaminergic activity to promote neuroplasticity and an antidepressant 
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response. All but one of the 5-HT receptor subtypes act through a G-protein coupled 
metabotropic mechanism, which initiates cellular responses through the activation of 
intracellular signalling cascades. Chronic antidepressant treatment, presumably by 
promoting enhanced serotonergic synaptic availability and receptor signalling, has been 
found to up-regulate numerous components of the cAMP signal transduction pathway, 
including the effector protein kinase A (PKA) and the transcription factor cAMP-response-
element-binding protein (CREB) (Nestler et al., 1989; Nibuya et al., 1996; Pittenger & 
Duman, 2008). Notably, the cAMP-PKA-CREB cascade, which is implicated in synaptic 
plasticity, is downstream of a number stimulatory G-protein coupled receptors, including 
several serotonin receptor subtypes (Martinowich & Lu, 2008). As CREB is a key 
transcription factor involved in activity-dependent BDNF expression (Tao et al., 1998), the 
activation of CREB may be one of the mechanisms by which the antidepressant-induced 
elevation of monoamines acts to enhance BDNF expression and promote neuroplasticity. 
1.3 Antidepressant pharmacotherapy: Limited options & limited outcomes 
Nearly all currently marketed antidepressant medications act to increase the synaptic 
availability of monoamine neurotransmitters. This is achieved through one of two 
mechanisms: the prevention of degradation by inhibition of the enzyme monoamine 
oxidase, or the prevention of re-uptake from the synapse by inhibition of the reuptake 
transporter proteins. The three commonly prescribed classes of antidepressants include the 
Monoamine oxidase inhibitors (MAOIs), the tricyclic antidepressants (TCA), and the 
selective reuptake inhibitors (SRIs), including selective serotonin reuptake inhibitors (SSRIs), 
and serotonin-norepinephrine reuptake inhibitors (SNRIs). 
MAOIs: Among the first clinically introduced antidepressants, MAOIs cause inhibition of 
the monoamine oxidase enzyme, which acts to degrade serotonin, norepinephrine and 
dopamine. In the brain, monoamine oxidase (MAO) regulates the cytoplasmic concentration 
of monoamine neurotransmitters, thus, the primary effect of MAOIs is to increase the 
cytoplasmic concentration of monoamines, thereby promoting spontaneous transmitter 
leakage and enhanced synaptic action. The enzyme isoform MAO-A is the primary target of 
MAOI-type antidepressants, and is responsible for the antidepressant effect. However, most 
MAOIs are not particularly selective, inhibiting both MAO-A and MAO-B isoforms, as well 
as several other enzymes, including those involved in drug metabolism. These non-specific 
interactions contribute to an extensive profile of serious adverse effects including 
cardiovascular complications, dietary interactions, drug interactions, and lethality in 
overdose.  
TCAs: Another class of early antidepressants, tricyclic compounds (so named for their 
characteristic three-ringed chemical structure) were initially synthesized as potential 
antipsychotic drugs, and though found ineffective in psychosis, they did exert potent 
antidepressive effects. TCAs act to inhibit the reuptake of monoamines from the synapse by 
blocking reuptake transporters, the primary mechanism by which the length of the synaptic 
signal is regulated and the actions of monoamine neurotransmitters are terminated. This 
action enhances the synaptic availability of monoamine neurotransmitters. All of the three 
major classes of monoamine transporter proteins, the serotonin transporter (SERT or 5-
HTT), the norepinephrine transporter (NET) and to a lesser extent the dopamine transporter 
(DAT), are inhibited by TCAs. As with MAOIs, the non-selective pharmacological profile of 
TCAs contributes to a host of unwanted effects, including inhibition of various types of 
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neurotransmitter receptors, cardiovascular effects, sedation, drug interactions, and lethality 
in overdose. 
SRIs: The diverse systemic side effect profiles of MAOIs and TCAs, coupled with the toxic 
effects in overdose that lead to the frequent use of these compounds in suicide attempts, 
prompted the development of new antidepressants that would be safer and more tolerable – 
what resulted was a diverse class of second-generation reuptake inhibitors whose clinical 
use rapidly overtook that of MAOIs and TCAs. Of all the available types of antidepressant 
drugs, selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed. 
Acting in a manner analogous to TCAs, these second generation compounds block 
monoamine reuptake, but exhibit selectivity for blocking SERT and/or NET. While the 
profile of adverse drug effects of SRIs is more favourable than that of MAOIs or TCAs, these 
antidepressants still exhibit considerable side effects including the nonspecific inhibition of 
ion channels and neurotransmitter receptors, and even, surprisingly, an increased risk of 
suicide.  
 
Drug Class Examples Conventional Mode of Action 
MAOIs 
Phenelzine 
Rasagiline 
Moclobemide 
Iproniazid 
 
Monoamine Oxidase Inhibition 
(MAO-A) 
 
TCAs 
Imipramine 
Amitriptyline 
Doxepin 
Desipramine 
 
Monoamine Reuptake Transporter 
Inhibition (SERT, NET, DAT) 
SRIs 
SSRI 
Fluoxetine 
Paroxetine 
Citalopram 
Sertaline 
 
Selective Serotonin Reuptake 
Inhibition (SERT) 
 
SNRI 
Venlafaxine 
Duloxetine 
Serotonin-Norepinephrine 
Reuptake Inhibition (SERT, NET) 
Table 1. Classification of monoaminergic antidepressant drugs according to the 
conventional mechanism of action. 
The advent of second-generation SRIs with a superior safety profile improved the 
pharmacological management of depression; however, this advance was not paralleled by 
an improvement in the clinical outcome of MDD pharmacotherapy. MAOIs, TCAs, and SRIs 
all require several weeks of continuous treatment for an improvement of depressive 
symptoms to appear, meanwhile the response rate is abysmally low and the relapse rate is 
high. Only approximately 60 percent of patients receiving antidepressants experience a 
meaningful improvement of depressive symptoms, with as little as one third experiencing 
full remission (Trivedi et al., 2006; Thase et al., 2005). A further disadvantage of the available 
plethora of antidepressant medications is the fact that they all essentially work through the 
same monoaminergic mechanism. Thus, attempting combinatorial therapy or a series of 
different medications in attempts to gain improvement in the clinical management of MDD 
faces fundamental mechanistic limitations, though this is a commonly employed but largely 
unproven clinical strategy (Thase, 2011). Whereas SRIs have to some extent addressed the 
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adverse side effect profile of antidepressants, the efficacy and time course of therapeutic 
action are two critical aspects of antidepressant therapeutics that still must be improved.  
1.4 Side effects of antidepressant pharmacotherapy: Consequences of high 
therapeutic doses & non-specific drug effects 
Antidepressants are notoriously promiscuous substances, indiscriminately affecting a wide 
range of ion channels, neurotransmitter receptors, and synaptic plasticity mechanisms that 
ultimately results in changes in neuronal architecture and function. While these non-specific 
effects have been suggested to be essential for producing the antidepressant response, the 
fact that we do not know the mechanism of therapeutic action of antidepressants makes it 
difficult to separate the beneficial from the detrimental effects of these non-specific 
interactions.  
With the reuptake blocker type of antidepressants (including TCAs and SRIs), there exists a 
100-1,000 fold-magnitude of difference between the concentrations at which selective 
inhibition of monoamine reuptake and the therapeutic antidepressant effect occurs (Bolo et 
al., 2000; Torres et al., 2003; Lenkey et al., 2006). The high concentrations required for 
therapeutic efficacy result in a substantial loss of drug specificity. Within the therapeutic 
window (e.g. steady state brain concentrations in the low micromolar range), 
antidepressants affect a number of protein targets, inhibiting numerous types of ion 
channels and neurotransmitter receptors, which are critical components of neuronal 
electrical excitability and network activity. Documented interactions of antidepressant drugs 
include calcium, sodium and potassium channels, as well as serotonergic, adrenergic, 
dopaminergic, glutamatergic, and cholinergic receptors. The movement of ions through 
voltage- and ligand-gated channels underlies virtually every aspect of neuronal function – 
action potential generation and synaptic communication being two principle examples. 
Calcium (Ca2+) ions in particular have a critical function as a second messengers in 
intracellular signalling, regulating numerous neuronal events such as the activation of Ca2+-
dependent proteins, the initiation of gene expression, neurite outgrowth, synapse formation, 
neurotransmitter release and synaptic plasticity (Feng et al., 2002; Xu et al., 2009; 
Hardingham et al., 1997). As the cardiovascular system similarly depends on ionic influx 
(i.e. Ca2+ for heart contraction) and neurotransmitter regulation, this opens to the possibility 
that the non-specific interactions of antidepressant drugs with voltage gated ion channels 
and neurotransmitter receptors can produce systemic dysregulation, as is seen in the 
cardiotoxic lethality in TCA overdose. Ultimately, the blind modulation of protein targets by 
antidepressant drugs contributes to systemic and neuronal side effects that may have 
devastating consequences.  
A fundamental principle of therapeutic intervention is that the derived benefit of the 
therapy must outweigh the potential risks. Antidepressant medications are readily used as 
the first-line standard of treatment for the management of MDD, as depression constitutes a 
substantial personal and economic burden, and the risks associated with untreated 
depression are substantial (i.e. diminished quality of life, loss of productivity, comorbid 
diseases, suicide). In accordance with the increasing clinical prevalence of MDD, the use of 
antidepressant drugs has grown rapidly, being the most commonly prescribed class of 
medication; SSRIs in particular, with their comparatively innocuous profile of serious 
adverse effects, are the most widely used type of antidepressant (Olfson & Marcus, 2009). In 
light of the potential negative effects arising from the often overlooked non-specific 
interactions of antidepressant drugs, the limited benefit of antidepressants raises 
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considerable grounds for concern. Indeed, despite their widespread use, the risk-benefit 
ratio of antidepressant drugs is somewhat controversial. In addition to the less-than-optimal 
response and remission rates resulting from antidepressant pharmacotherapy, the actual 
pharmacological benefit of antidepressants in the majority of patients – those below the 
threshold of ‘very severe’ depression – is largely unfounded. In a patient-level meta-
analysis, Fournier et al. (2010) demonstrated that the magnitude of response to 
antidepressant therapy depends on the baseline depression symptom severity; such that 
compared to placebo, patients with mild to severe depression do not derive significant 
benefit from antidepressant pharmacotherapy. Furthermore, these patients with less  
 
Target Drug Reference 
Ion channels 
Sodium (Na+) 
channels 
 Fluoxetine, 
Amitriptyline, 
Desipramine, Doxepin
Pancrazio et al., 1998 
 
Nav1.3, Nav1.4, 
Nav1.7 
Duloxetine, Sertraline, 
Paroxetine 
Wang et al., 2008;  
Wang et al., 2010 
 Citalopram Pacher & Kecskemeti, 
2004
Potassium (K+) 
channels 
HERG  Citalopram Witchel et al., 2002 
GIRK  Citalopram, Imipramine, 
Amitriptyline 
Kobayashi et al., 2004 
 
KV1.5  Citalopram Lee et al., 2010 
KV1.1  Fluoxetine Yeung et al., 1999 
KV3.1  Fluoxetine Sung et al., 2008 
Calcium (Ca2+) 
channels 
T, N, L- type Fluoxetine, Citalopram Deák et al., 2000;  
Witchel et al., 2002 
P/Q-type Fluoxetine Wang et al., 2003 
Neurotransmitter Receptors 
N-Methyl-D-aspartate 
(NMDA) 
Desipramine, 
 Imipramine 
Sernagor et al., 1989; 
Reynolds & Miller, 1988 
Glycine Fluoxetine Ye et al., 2008 
Nicotinic Acetylcholine  
(nACh) 
Fluoxetine García-Colunga et al., 
1997 
Imipramine, Rana et al., 1993 
Muscarinic Acetylcholine (mACh) Imipramine Snyder & Yamamura, 
1977
Serotonin 
(5-HT3) 
Fluoxetine, Phenelzine, 
Imipramine, Iproniazid 
Fan et al., 1994 
Table 2. Highlight of some of the known ion channel and neurotransmitter receptor targets 
of antidepressant drugs. 
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severe depressions represent the majority of clinical cases, and are frequently excluded from 
clinical trials establishing antidepressant drug efficacy, where inclusion often requires a 
minimum baseline symptom severity (Zimmerman et al., 2002). This apparent lack of a 
meaningful drug response for a large percentage of the MDD patient population tips the 
balance of the risk-benefit assessment of antidepressant pharmacotherapy, giving rise to the 
question – could antidepressant therapy be causing more harm than good? 
2. Insights from a single-synapse experimental model 
In addition to its function as a modulatory neurotransmitter in the adult brain, serotonin also 
plays a role in numerous neurodevelopmental events, including synaptogenesis and the 
wiring of brain circuits (Gaspar et al., 2003). As antidepressants are known to cross the 
placental barrier, numerous clinical and animal model studies have investigated the impact of 
gestational antidepressant exposure, and have identified the occurrence of severe 
neurodevelopmental birth defects, neuronal network mis-wiring complications, and sustained 
neurobehavioural effects in association with in utero exposure (Alwan et al., 2007; Xu et al., 
2004; Homberg et al., 2009; Oberlander et al., 2009). It is, however, difficult to differentiate 
between the developmental effects of the maternal mental illness (in clinical studies), excessive 
levels of serotonin caused by the action of antidepressant drugs, and the non-specific 
interactions of antidepressants. Identifying the contribution of each of these factors to 
developmental complications is difficult to assess in the context of complex in vivo models. 
Similar neurodevelopmental events, such as neurogenesis, synaptogenesis and synaptic 
plasticity, occur throughout adulthood, where they are believed to underlie adaptive processes 
such as learning and memory. If the non-specific actions of antidepressant drugs do in fact 
play a role in the disruption of neuronal architecture and function in the developing brain, 
then the possibility also exists that the dynamic adult brain may be similarly susceptible, 
raising new concerns for the potential adverse effects of antidepressant drugs.  
 
 
Fig. 1. The in vitro neuronal culture model of Lymnaea stagnalis. A. Neurons cultured in the 
presence of growth factors extend neurite processes and form synaptic networks with 
neighboring neurons (arrow). Growth cones (asterisk) actively sense and navigate the 
environment. Scale bar represents 50 μm. B. The soma-soma single synapse experimental 
model. When the somas (cell bodies) of neurons are juxtaposed in culture, synaptogenesis 
occurs without the reliance on neurite outgrowth. Scale bar represents 25 μm. 
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Our interest in investigating the impact of non-specific antidepressant effects on synapse 
formation and synaptic function was initiated by the fact that antidepressant drugs 
indiscriminately inhibit ion channels, and that neurotrophic signalling and synaptic plasticity 
mechanisms appear to be necessary for the antidepressant response. Our group employs a 
simple in vitro experimental model to explore the cellular and molecular mechanisms of 
synapse formation. With the invertebrate model system Lymnaea stagnalis, functionally defined 
individual neurons with known neurotransmitter phenotype can be isolated and cultured in 
vitro. In the presence of neurotrophic factors, these neurons regenerate neuronal processes, 
recapitulate specific synaptic connectivity and establish functional neuronal networks, 
resembling the developmental events seen in vivo (Syed et al., 1990; Ridgway et al., 1991; Feng 
et al., 1997). As this model enables the study of individual neurons, synapse formation and 
synaptic activity at the level of the single synapse, it provides us with a unique opportunity to 
isolate the impact of the non-specific interactions of antidepressant drugs on neuronal 
viability, synaptic function, and neurotrophic factor-dependent synaptogenesis.  
2.1 Review of key findings from our comparative evaluation of the neuronal effects of 
the non-specific actions of two SSRI-type antidepressants 
SSRIs represent the most widely used type of antidepressant medication, and though their 
action is largely regarded to be specific, or at least the most specific of available medications, 
there is a growing body of evidence that these compounds indiscriminately affect various 
aspects of neuronal function, primarily through the non-specific inhibition of ion channels 
and neurotransmitter receptors. For our investigation, we opted to conduct a comparative 
analysis of two commonly prescribed SSRI-type antidepressant drugs, fluoxetine and 
citalopram. Fluoxetine was the first and the most obvious choice for investigation, as it was 
the first clinically introduced SSRI and is furthermore the most commonly used compound 
in experimental settings. Within the SSRI class of antidepressants, however, fluoxetine 
exhibits the lowest degree of selectivity for serotonin reuptake, whereas citalopram is the 
most selective, and additionally is a more potent inhibitor of serotonin reuptake than 
fluoxetine (Hyttel, 1994). This lends to the possibility that citalopram may produce an 
antidepressant effect at lower therapeutic concentrations, thereby reducing the risk of non-
specific inhibitory actions. These pharmacological characteristics lent to the formulation of 
our hypothesis that different SSRIs would exert characteristic non-specific neuronal side 
effects, and, because of its lesser selectivity profile, that fluoxetine would exert a more 
detrimental effect on synaptic physiology than citalopram. Using a combination of 
intracellular and patch-clamp electrophysiological recordings, calcium imaging, 
immunocytochemistry and various neuroimaging techniques, we have for the first time 
demonstrated that clinically-relevant concentrations of fluoxetine, but not citalopram 
(dosage range up to 5 μg/mL; Bolo et al., 2000), exhibit detrimental effects on neurite 
outgrowth, synapse formation, synaptic transmission and synaptic plasticity, and that the 
negative effects of fluoxetine on synaptic function involves a direct perturbation of both pre- 
and post-synaptic machinery (Xu et al., 2010; Getz et al., 2011). 
2.1.1 Fluoxetine inhibits the initiation of neurite outgrowth and induces growth cone 
collapse and neurite retraction 
The Effect: Neurite outgrowth is the initial and essential step prior to synapse formation, and 
is easily and routinely modelled experimentally. We therefore first sought to investigate the 
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non-specific neuronal effects of SSRIs by examining their impact on neurite outgrowth. To 
this end, Lymnaea serotonergic or non-serotonergic neurons were cultured under control 
conditions (in the presence of growth media containing neurotrophic factors), or in the 
presence of SSRIs over a therapeutically-relevant dosage range. The neuronal ability to 
initiate and elongate neurite processes, spread branches and form active growth cones was 
monitored under these two conditions (Xu et al., 2010). We found that neurons cultured in 
growth media alone established extensive neurite outgrowth (massive branches with active 
growth cones), while neurons cultured in the presence of fluoxetine exhibited only minimal 
branches and shorter processes at lower doses (< 3 μg/mL), and no growth at higher 
concentrations (> 3 μg/mL). In neurons that had developed active growth cones, exposure 
to fluoxetine resulted in the collapse of growth cones within minutes, and the retraction of 
neurite processes within hours. These negative effects of fluoxetine were observed in 
Lymnaea neurons regardless of their neurotransmitter phenotype. We also performed a 
similar investigation using mammalian neurons to determine whether the inhibitory effects 
of fluoxetine may be attributed to the invertebrate preparation used. Fluoxetine was 
similarly found to inhibit neurite outgrowth and disrupt neuronal network assembly in both  
 
 
Fig. 2. Acute application of fluoxetine, but not citalopram, causes rapid growth cone collapse 
and neurite retraction. Lymnaea neurons were cultured in the presence of growth factors and 
allowed to develop neurite outgrowth with active growth cones (arrow). Within 30 minutes 
of fluoxetine exposure, all growth cones exhibited collapsed morphology, whereas citalopram 
application resulted in no discernable detrimental effect. Scale bar represents 50 μm 
www.intechopen.com
 
Mental Illnesses – Evaluation, Treatments and Implications 342 
rat primary cortical neurons and neurohybridoma cells homologous to dorsal root ganglion 
neurons, thus validating our findings of the inhibitory effects of fluoxetine in Lymnaea 
neurons. As the negative effect of fluoxetine on neurite outgrowth and growth cone 
morphology was observed in neurons regardless of vertebrate or invertebrate, serotonergic 
or non-serotonergic phenotype, these findings suggest that fluoxetine possesses non-specific 
effects that are independent of its mechanistic action as an SSRI. Interestingly, exposure to 
citalopram did not exhibit negative effects on neurite outgrowth or growth cone 
morphology (Getz et al., unpublished observations), suggesting that the negative effects 
observed for fluoxetine may be a drug-specific property, and not a common feature of the 
SSRI class of antidepressants. 
The Mechanism: Optimal calcium transients in growth cones have been shown to be essential 
for the regulation of the polymerization and depolymerisation status of cytoskeletal proteins 
including F-actin, and thus affect growth cone motility and behaviour (Spira et al., 2001; 
Welnhofer et al., 1999; Henley & Poo, 2004). In the presence of trophic factors, the growth 
cones of Lymnaea neurons exhibit small spontaneous Ca2+ transients, and these Ca2+ 
transients were eliminated within minutes of exposure to fluoxetine (Xu et al., 2010). 
Furthermore, immunocytochemical labeling identified that the fluoxetine-induced inhibition 
of spontaneous Ca2+ transients and collapse of growth cones was accompanied by a 
breakdown of the F-actin cytoskeleton. Thus, the perturbation of Ca2+ homeostasis in 
neuronal growth cones by the non-specific actions of fluoxetine contributes to its 
detrimental effect on neuronal architecture.  
2.1.2 Fluoxetine, but not citalopram, inhibits synapse formation 
The Effect: Because fluoxetine was found to prevent neurite outgrowth and neuronal 
network assembly, the use of the soma-soma synapse model, where synapse formation 
occurs in the absence of neuronal outgrowth, enabled us to investigate how the non-specific 
effects of SSRIs might affect the development of functional synapses. When paired in a 
soma-soma configuration, the identified Lymnaea neurons visceral dorsal 4 (VD4) and left 
pedal dorsal 1 (LPeD1) form a well characterized excitatory cholinergic synapse, in which 
VD4 functions presynaptically, and LPeD1 functions as the postsynaptic partner. As SSRIs 
distribute throughout the brain, their actions are not limited to monoaminergic neurons, 
thus the investigation of the non-specific effects of SSRIs on synaptogenesis and synaptic 
function in other neuronal systems is warranted. To determine whether SSRI exposure 
affects synaptogenesis between VD4 and LPeD1, these neurons were cultured in the soma-
soma configuration in the presence of various concentrations of fluoxetine or citalopram. 
Simultaneous recordings of presynaptic action potentials (current injection-induced) and 
postsynaptic potentials (PSPs) were made to determine the effect of SSRI exposure on the 
incidence of synapse formation, by measuring the percentage of cells that exhibited a 
functional synapse, and the synaptic strength, by measuring the mean amplitude of PSPs in 
response to the presynaptic action potential. When cultured in the presence of fluoxetine, 
neuron pairs exhibited a dose-dependent reduction in both the incidence of synaptogenesis, 
and, in pairs that did form synapses, a reduction in synaptic efficacy, which was significant 
at higher concentrations. Interestingly, citalopram had no detrimental effect on either the 
incidence of synapse formation or synaptic efficacy. Again, these findings lend support to 
our hypothesis that different SSRIs exhibit characteristic non-specific neuronal effects, and 
that fluoxetine is more detrimental than citalopram. 
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Fig. 3. The simultaneous intracellular electrophysiological recording protocol used in the 
soma-soma synapse model. Current injection in the presynaptic neuron (pre, VD4) results in 
the generation of an action potential (AP), which triggers release of neurotransmitter. The 
efficacy of synaptic transmission can be measured through the amplitude of the resultant 
excitatory post-synaptic potential (PSP) generated in the postsynaptic neuron (post, LPeD1). 
Triggering AP burst firing (tetanus) in the presynaptic neuron results in the induction of a 
use-dependent form of synaptic plasticity, pots-tetanic potentiation (PTP), measured as the 
ratio of PTP over PSP increase (dotted line). The efficacy of synaptic transmission rapidly 
returns to baseline values (asterisk), demonstrating the use-dependent characteristic of this 
type of synaptic plasticity. 
The Mechanism: Using the in vitro soma-soma preparation, we have recently found that 
neurotrophic factor signalling, through triggering Ca2+ influx via voltage-gated calcium 
channels in the postsynaptic cell and the subsequent expression of excitatory 
neurotransmitter receptors, is essential for the formation of excitatory synapses (Xu et al., 
2009). These trophic factor-mediated intracellular Ca2+ oscillations required for excitatory 
synapse formation were inhibited in the presence of fluoxetine, indicating that fluoxetine 
prevents the expression of proteins involved in synaptogenesis (Xu et al., 2010). Attesting to 
this, we found that the expression and synaptic localization of synaptophysin, a synaptic 
vesicle-associated protein and presynaptic biomarker, were significantly reduced in 
synapses formed in the presence of fluoxetine, but not citalopram (Getz et al., 2011). 
Importantly, we also demonstrated that the inhibitory effect of fluoxetine on synapse 
formation is reversible following prolonged drug washout, and that this recovery is 
dependent on protein synthesis – that is, new synapses developed following the removal of 
fluoxetine. Together, these data suggest that fluoxetine, through the non-specific inhibition 
of Ca2+ signalling and Ca2+-dependent gene expression, affects the assembly of synaptic 
machinery during synapse formation, and that this contributes to a sustained, albeit 
reversible impairment of synaptogenesis.  
2.1.3 Acute exposure to fluoxetine and citalopram affects transmission at established 
synapses 
The Effect: Through the inhibition of ion channel and neurotransmitter receptor activity, the 
non-specific interactions of SSRIs also have the potential to augment the function of existing 
synapses. To determine whether neuronal communication at established synapses is 
www.intechopen.com
 
Mental Illnesses – Evaluation, Treatments and Implications 344 
affected by SSRI exposure, we measured the efficacy of synaptic transmission between VD4-
LPeD1 soma-soma paired neurons following the acute application of various concentrations 
of fluoxetine or citalopram. Again, using simultaneous pre- and post-synaptic 
electrophysiological recordings, the mean amplitude of the PSP provided an indication of 
synaptic strength, which was recorded before, during and after washout of SSRIs. Following 
exposure to fluoxetine, the efficacy of synaptic transmission was significantly reduced at all 
doses examined, and this inhibition was not reversible after a brief washout period. 
Surprisingly, acute exposure of neuron pairs to citalopram also resulted in a reduction of 
synaptic transmission efficacy; however, this effect was significant only at the highest 
concentration evaluated. Moreover, we found that exposure to fluoxetine, and to some 
extent high concentrations of citalopram, often resulted in the development of presynaptic 
action potential clamping during burst firing (inability to sustain continuous trains of action 
potentials), suggesting that the intrinsic membrane properties of the neurons may be 
affected by both fluoxetine and citalopram exposure, for example, through the non-specific 
inhibition of the sodium and potassium channels that generate the action potential. 
Established synapses also exhibit the property of synaptic plasticity, such that synaptic 
communication is not fixed, but has the capacity to change in response to modulations of 
neuronal activity patterns. The VD4-LPeD1 synapse exhibits a well characterized use-
dependent form of short term plasticity known as post-tetanic potentiation (PTP), which is 
initiated during periods of bursting activity in the presynaptic neuron. Taking this 
advantage, we investigated whether the inhibition of action potential burst firing resulting 
from acute SSRI exposure might also affect the occurrence of synaptic plasticity. 
Interestingly, whereas PTP was not affected by citalopram, exposure to fluoxetine almost 
completely inhibited the induction of PTP. As both SSRIs were found to affect synaptic 
transmission at established synapses, yet only fluoxetine affected synaptic plasticity, we 
postulate that the profiles of inhibitory effects on ion channels and neurotransmitter 
receptors are unique for these two drugs, and that these drug-specific pharmacological 
characteristics contribute to the differential neuronal effects seen for fluoxetine and 
citalopram. 
The Mechanism: Synaptic machinery, the components at the synapse that mediate 
presynaptic neurotransmitter release and the postsynaptic response, must function 
collectively in order for proper synaptic transmission to occur. Presynaptically, the action 
potential triggers the influx of Ca2+ through the opening of N-type voltage-gated calcium 
channels, whereby Ca2+-sensing proteins associated with the synaptic vesicle activate to 
trigger the release of neurotransmitter into the synaptic cleft. Postsynaptically, released 
neurotransmitters bind to either ionotropic receptors that produce depolarizing or 
hyperpolarizing currents in the postsynaptic cell to transfer information between neurons, 
or metabotropic receptors that activate signalling cascades to affect neuronal activity. Using 
whole-cell patch clamp recordings, we found that the Ca2+ current in the presynaptic VD4 
neuron was significantly reduced after exposure to fluoxetine, but not citalopram, indicating 
that a direct inhibition of Ca2+ influx through voltage-gated calcium channels contributes to 
the fluoxetine-mediated inhibition of synaptic transmission. Furthermore, ratiometric Ca2+ 
imaging revealed that the influx of Ca2+ during action potential burst firing was significantly 
reduced by both fluoxetine and citalopram, suggesting that a loss of depolarizing driving 
force (i.e. through the inhibition of sodium and/or potassium channels and the 
development of action potential clamping) and subsequent indirect reduction in Ca2+ entry 
is most likely responsible for the citalopram-mediated reduction of synaptic transmission 
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(Getz et al., 2011). In Lymnaea neurons, the mechanism underlying the short-term plasticity 
of PTP has been shown to involve presynaptic Ca2+ entry through voltage-gated calcium 
channels and subsequent activation of CaMKII, a protein kinase that mediates the effects of 
intracellular signalling cascades (Luk et al., 2011). This mechanism illuminates how the 
differential effects of fluoxetine and citalopram on synaptic plasticity can be produced by 
their respective direct and indirect inhibition of presynaptic Ca2+ entry. Finally, we 
examined the amplitude of the receptor potential generated in the postsynaptic neuron in 
response to exogenously applied acetylcholine to determine whether the postsynaptic 
machinery was also affected by SSRI exposure. Indeed, in the presence of fluoxetine, but not 
citalopram, the receptor potential was significantly reduced, indicating that the inhibition of 
neurotransmitter receptors is another mechanism by which the non-specific actions of 
fluoxetine contributed to the reduction of synaptic transmission efficacy. Ultimately, we find 
that the negative effect of fluoxetine on synaptic function is attributable to the direct 
perturbation of numerous components of both pre- and post-synaptic machinery, whereas 
citalopram exhibits only a minor profile of adverse effects in established synapses, again 
providing support for the hypothesis that the distinctive auxiliary neuronal effects arise 
from the characteristic non-specific interactions of SSRIs. 
2.1.4 The inhibitory effects of SSRIs on neuronal function: It all comes down to 
calcium 
The occurrence of non-specific ion channel and neurotransmitter receptor inhibition by 
SSRIs is widely acknowledged; however, the potential impact of these effects remains 
largely disregarded. Taken together, our findings reveal that these non-specific interactions 
do in fact hold unforeseen consequences for both neurodevelopmental events and synaptic 
function. Nearly all of the neuronal functions impacted by fluoxetine can be either directly 
or indirectly attributed to calcium and its critical function as a cytosolic messenger, 
mediating such diverse neuronal effects as cytoskeletal dynamics, growth cone activity, 
gene expression, neurotransmitter release, and synaptic plasticity. As citalopram did not 
directly affect Ca2+ influx through voltage-gated calcium channels, and is additionally 
associated with a comparatively benign profile of adverse neuronal effects, we propose that 
the disruption of calcium homeostasis by fluoxetine is the primary causal factor underlying 
the extensive profile of detrimental neuronal effects attributed to this SSRI.  
 
Neuronal Phenomenon Ca2+-dependent? 
Fluoxetine 
Inhibition 
Citalopram 
Inhibition 
Neurite outgrowth Yes Yes No 
Growth cone dynamics Yes Yes No 
Synapse formation Yes Yes No 
Synaptic transmission Yes Yes Yes 
Synaptic plasticity (PTP) Yes Yes No 
Presynaptic ICa Yes Yes No 
 
Table 3. Summary of the differential effects fluoxetine and citalopram exhibit on neuronal 
architecture and function. 
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Fig. 4. The proposed mechanisms of non-specific action of SSRIs that contribute to the 
development of inhibitory effects on neuronal structure and function. Our data suggests 
that the principle mechanism underlying the fluoxetine-mediated disruption of neuronal 
function is the inhibition of intracellular calcium signalling. This interferes with numerous 
neuronal processes including neurotrophic factor signalling through receptor tyrosine 
kinase (RTK), synaptic protein expression (i.e. synaptophysin, the postsynaptic nACh 
receptor), synaptogenesis, membrane excitability, and synaptic neurotransmitter release. As 
citalopram did not exhibit a similar profile of detrimental effects, and did not directly inhibit 
intracellular calcium influx, we propose that citalopram-mediated disruption of synaptic 
transmission efficacy may result from the reduction of neuronal excitability, for instance, 
through the inhibition of the Na+ and/or K+ channels that contribute to the development of 
action potentials and the regulation of neuronal excitability. 
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While the impact of the promiscuous interactions of antidepressant medications remains 
largely unaccounted for, we find that one in particular – the modulation of calcium channel 
activity – can have devastating consequences for neuronal structure and synaptic function. 
Ultimately, in light of the low clinical efficacy of antidepressant medications and our limited 
understanding of the mechanism(s) of antidepressant action, the benefits of antidepressant 
pharmacotherapy, in some instances, may not outweigh the risks. 
3. Conclusions: Looking to the future of antidepressant therapeutics 
After more than half a century of development in the field of antidepressant 
pharmacotherapy, there has not been a significant improvement in the treatment 
paradigm or the therapeutic outcome. The last advance came in the 1990’s with the 
introduction of the SRI class of antidepressants, which, to some extent, addressed the 
need for safer and more tolerable compounds, but left the issues of efficacy and time 
course of therapeutic action largely unresolved. Assessing the clinical safety of these 
compounds is complicated by the fact we do not completely understand the mechanism of 
therapeutic action – making it difficult to differentiate between what may be a necessary 
effect for therapeutic response and a detrimental effect resulting from non-specific 
interactions of SRIs with ion channels and neurotransmitter receptors. The limited efficacy 
profiles, long periods of therapeutic lag, and as we have identified, the potential for 
inhibitory effects on neuronal function arising from the non-specific interactions of 
antidepressant medications, underscores the need to develop more selective and more 
effective therapeutics for the treatment of MDD.  
Further development in this field has been hindered by lack of certainty regarding the 
etiology of depression. Indeed, the complex multifactorial nature of MDD provides no 
obvious starting points for molecular investigation, and this situation is further 
confounded by the fact that much of what we currently understand about depression has 
been gleaned from observing the effects of antidepressant drugs, which themselves 
appear to act through convoluted and indirect secondary mechanisms. Though slow to 
gain recognition, the alternative neuroplasticity theory of depression posits that structural 
changes and neuroplasticity deficits are causative factors underlying MDD, and thus 
opens to the possibility that these pathways may be targeted directly in attempts to 
improve therapeutic outcome and perhaps also to reduce the unwanted non-specific 
effects associated with current antidepressant drugs. An exciting new therapeutic strategy 
that has made its way into clinical trials involves the use of the psychotropic drug 
ketamine, which acts as a glutamate NMDA receptor antagonist. Fascinatingly, a single 
dose of ketamine has been found to produce a rapid (occurring within hours) and 
sustained (lasting as long as two weeks) antidepressant response through the rapid 
activation of synaptic plasticity mechanisms (Berman et al., 2000; Li et al., 2010). However, 
the clinical use of ketamine is limited by its psychotrophic effects and the potential for 
abuse. Subunit-selective NMDA receptor antagonists that produce an antidepressant 
response without the development of a psychotropic reaction have more recently been 
developed and tested clinically, providing an alternate means to achieve the rapid acting 
antidepressant effects without the side effects and potential complications (Preskorn et al., 
2008). As numerous antidepressant drugs have been found to antagonize NMDA receptor 
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activity, it is possible that current antidepressant drugs may also be acting through this 
mechanism – just taking a roundabout and rather ineffectual way of getting there, hence 
the therapeutic delay and high concentration required for antidepressant response. Herein 
we find a striking example of the difficulty in interpreting the effects of antidepressant 
medications without a clear understanding of their mechanism of action, and how this 
impacts neuronal function.  
There is an unmistakable need for a solution to the problems of the high rates of morbidity 
and mortality present during the extended window of therapeutic inefficacy associated with 
traditional antidepressants, and the cryptic consequences of their non-specific interactions. 
The fact that NMDA receptor antagonists produce an antidepressant response with just a 
single dose, and that this response is sustained beyond the period of drug metabolism and 
elimination, highlights the potential for this therapeutic strategy to have minimal non-
specific interactions and adverse effects, providing a significant advantage over currently 
available antidepressant medications. Furthermore, as the onset of antidepressant action of 
NMDA receptor antagonists is extremely rapid, the limitation of therapeutic lag associated 
with traditional antidepressants is also addressed. Given the compelling evidence to date, it 
appears as though NMDA receptor antagonists and the mechanisms of synaptic plasticity 
may provide a route towards the ’magic-bullet’ for depression pharmacotherapy that we 
have been searching for. 
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